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NARCOTIC DRUGS IN THE POSTANESTHETIC RECOVERY ROOM
JOHN W . DITZLER, M.D., PAUL R . D U M K E , M.D. and

BEVERLY COLLIER,

M.D.

I N THE PAST FEW YEARS, several briefs have been presented regarding abandonment
of narcotics in the pre-anesthetic medication regime of patients. Similar reasoning
might be applied as regards their use in the postanesthetic recovery room. It is our
position that irrespective of valid arguments, pro or con, we nonetheless find it
expedient to use narcotics for postanesthetic recovery room (PARR) patients who
exhibit signs of pain.
It has been well documented that even though clinically undetectable all
narcotics in therapeutically effective doses depress respiration." Previous studies
have shown that narcotics depress the vasomotor system and one, not infrequently,
sees serious hypotensive episodes in the patients in the PARR following the exhibition
of narcotics. Our interest has been in finding an effective narcotic for the treatment
of pain in the immediate postanesthetic state with the least depressant effect on the
cardiovascular system.
During a recent 18 month period we have taken a closer look at several
narcotics as they pertain to our PARR practice. To put the patient receiving
narcotics in our PARR in proper perspective let us point out several features of
our practice.
Patients were kept in the recovery room until oriented as to name, time,
place and ability to cooperate with the nurse and until vital signs were stable at
or near the pre-operative level. Data in Table I indicates that nearly one-third
of the padents having a surgical procedure were not returned to the PARR for
care. It further indicates that only 5 per cent of those patients cared for actually
received narcotics while in the PAAR. This low figure suggests the necessity of
proper evaluation of the postanesthetic, resdess, uncomfortable patient. Patients who
received narcotics were first adjudged by competent recovery room nurses and
Anesthesiology staff to be free of hypoxia, hypercarbia and hypotension. Patients
had also been reassured, urinary bladders emptied and position changes accomplished
where possible before considering use of narcotic drugs. The low incidence of
narcotic use is further reflected in various methods of anesthetic management. The
use of anesthetic methods and agents which employ pontocaine®-epinephrine solutions
for spinal anesthesia and cyclopropane, ether or nitrous oxide-ether for inhalational
From the Department of Anesthesiology.
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anesthesia tends to decrease the immediate postanesthetic need for pain relief as
contrasted with other methods employing thiopental, nitrous oxide and relaxants.
Although the definition of pain is elusive and nebulous, when the operative
procedure and the clinical appearance of the patient make it quite clear that pain
was present, we reUed upon narcotic drugs for pain rehef.
To further explain our interests in the use of narcotic drugs for the recovery
room patients, it must be pointed out that we have been generally disappointed in
all forms of so-called "ataractic" and "tranquilizer" drugs for postanesthetic and
surgical discomfort. Occasionally they work — too often, however, at the price of
cardiovascular instability and/or endless hours of more than desirable sleep. Likewise,
we have felt unconvinced of the necessity of adding various antiemetic drugs preoperatively, or of eliminating the preanesthetic narcotic, exceptions however always
being possible; these later practices also having some influence on the recovery room
state of our post-surgical patient.
When giving a narcotic for pain or restlessness in the PARR we have specific goals:
(1)

Rapid action.

(2)

A duration of 2-3 hours.

(3)

A patient who admits to feeling better and being relieved of
pain and discomfort.

(4)

Minimal depression of the cardiovascular and respiratory system.

(5)

A patient who does not require the individual full time attention
of the PARR nurse.

It is true we do not wish to depress respiration, but it has been our experience,
as well as that of others,' that respiration is depressed with therapeudc doses of all
narcotics, there probably being no exceptions. Rarely is there significant trouble
in the PARR from this standpoint, but cardiovascular homeostasis can be precipitously
jeopardized by most of the drugs available for relief of postoperative pain.
For years we have used meperidine, but we occasionally have seen profound
hypotension following its use in the PARR patient. We believed Demerol® to be
a fair drug, but were also favorably impressed with phenazocine (Prinadol). It
appeared that with this drug patients slept less, pain was well relieved, and they
Table I
HENRY FORD HOSPITAL
September, 1959 through February, 1961
Surgical Anesthetics
Regional Blocks, Locals and Others
Not Admitted to PARR
No. of Patients in PARR
No. of Patients Receiving Narcotics
% of Patients Receiving Narcotics
(of PARR Patients)
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21282
7775
13507
562
5%
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seemed rarely to get into circulatory trouble. T o see if our clinical impression was
justified we collected data on P A R R patients.
METHODS

Table I I indicates the narcotic drugs employed. We began by studying Demerol*
and Prinadol* but as others, such as Alvodine* and Numorphan,* appeared for use in
clinical practice, these were included. Almost as an oversight we included Morphine.
There were insufficient cases studied with 15 mg. of Morphine Sulfate so our reported
data include only 10 mg. doses of Morphine.
A l l drugs were supplied to the PARR in identical multiple dose 30 cc. vials labeled
as follows: "Narcotic: 1 cc. I . M . or Vi cc. I . V . " The understanding of PARR personnel
and Anesthesia staff was that if one gave I cc. of the drug he was giving a narcotic
equivalent to 50 mg. of Demerol. Clinical judgment decided the appropriate dose and
route. A periodic review (JWD) indicated this to have been valid and surprisingly
often indicated no significant difference whether the drug was given I . V . or I . M . ; and
doses of different drugs based upon body size equated well clinically. As seen in
Table I I I , two unknowns were used at a time. Ten such comparisons were made, eight
of which are indicated. Two of these were repeated. Table I V shows the final study,
with four drugs being tested concurrently and representing doses which clinically we
felt to be equi-analgesic. Table V indicates the total administrations of each drug.
Initially, the series was quite random with uncertainties as to equi-analgesic doses.
Halfway through the study, the codes were broken by one of us (PRD) and adjustments
made to more effectively equate comparable doses.
Table I I
HENRY FORD HOSPITAL
Narcotics Employed
Morphine
Morphine
Meperidine
Meperidine

10
15
50
100

mg.
mg.
mg. (a)
mg.

Oxymorphone
Oxymorphone
Phenazocine
Phenazocine

Piminodine Ethanesulfonate 20 mg. (d)
(a) Demerol®
(b) Numorphan®

1 mg. (b)
1.5 mg.
1 mg. (c)
2 mg.
(c) Prinadol®
(d) Alvodine®

Table I I I
HENRY FORD HOSPITAL
Comparison as "Unknowns"
Demerol 50 mg. and Phenazocine 2 mg.
Demerol 50 mg. and Numorphan I mg.
Phenazocine I mg. and Numorphan 1 mg.
Phenazocine 1 mg. and Numorphan 1.5 mg.
Phenazocine 2 mg. and Morphine 10 mg.
Phenazocine 2 mg. and Phenazocine 2 mg.
Numorphan 1.5 mg. and Demerol 100 mg.
Numorphan 1.5 mg. and Alvodine 20 mg.
* Demerol or
Prinadol or
Alvodine or
Numorphan

Meperidine—Winthrop Laboratories
Phenazocine—SKF
Piminodine Ethanesulfonate—Winthrop Laboratories
or Oxymorphone—Endo Laboratories
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RESULTS

Definition of terms becomes paramount, not only as to what most people
mean, but what the people evaluating these drugs meant. Let us consider first
the degree of pain relief.
Table V I shows the cumulative figures based on total administrations of each
drugs. Our delineation of Good, Fair and Poor pain relief is as follows: Good
results are generally defined as, when on direct question, the patient said he was
relieved and/or appeared quiet and sedate. This state had to persist, in general,
for at least one-half hour. Fair results were, in general, ascribed to patients who
while generally far less restless or expressing far less pain, still complained, said
pain relief was only partial. Poor was noted when littie or no result was observed.
Obviously, there is a spread between these definitions. Fair to Good was, on occasion,
described when the patient said his pain was partially relieved but the nurses felt
he had Good or Excellent results. Fair to Poor was ascribed usually when both
Table I V
HENRY FORD HOSPITAL — P.A.R.R.
Final Unknown Comparison
Demerol
Morphine
Alvodine

100 mg.
Numorphan
15 m.g.
Phenazocine
20 mg.
Accomplished Concurrently

1.5 mg.
2.0 mg.

Table V
Distribution of "Unknown" Drug Usage
Demerol
Numorphan
Phenazocine
Alvodine
Morphine
In 562 Patients

132
163
209
44
28
576

Administrations
Administrations
Administrations
Administrations
Administrations
Administrations

Table V I
PAIN RELIEF
(Based on Total Administrations of Each Drug)

%
Morphine
Demerol
Demerol
Phenazocine
Phenazocine
Alvodine
Numorphan
Numorphan

10
50
100
1
2
20
1
1.5

mg.
mg.
mg.
mg.
mg.
mg.
mg.
mg.

52
58
64
44
63
55
66
75
Good

%
24
24
24
31
25.5
33.5
23
16
Fair

%

%

24
76
18
82
12
88
25
7.^
11.5
88.5
11.5
88.5
11
89
9
91
Poor Good and

* % Obtaining Relief of Some Kind Unrelated to Time, Degree or Speed of Onset.
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patient and nurses or doctors felt there was little or no effect except perhaps 15
minutes of sedation and freedom from pain.
It is difficult for us to define statistically such broad definitions. A l l the
more so when rapidity of onset may make an observer call it a very good result,
even if it didn't qualify in all other respects. Duration, in the same way of action,
may influence one's judgment as to effectiveness. In Table V I , therefore, we have
placed in the "Good" column only those who clearly had good pain relief. The
Fair column lists those who were Fair and Fair to Good, and the Poor column
those Fair to Poor and Poor.
If one considers Good pain relief only, 1.5 mg. Numorphan was the unquestioned
best therapy. Close seconds, however, were obtained with 1 mg. of Numorphan, 2 mg.
Phenazocine and 100 mg. Demerol. If, on the other hand, one wishes to use a
drug which will produce the least number of Poor results (as seen in the third
column of Table V I ) one can add Alvodine 20 mg. to the aforementioned good
drugs. The column to the extreme right of Table V I was prepared to show all
Good, Fair to Good and Fair results grouped together. These figures represent the
percentage of patients receiving the drug who got some rehef irrespective of onset
time, degree of relief or duration. With the exceptions of Morphine Sulfate 10 mg.,
Demerol 50 mg. and Phenazocine 1 mg. all the studied drugs provided nearly equal
pain relief.

Table V I I
Phenazocine Pain Rehef Sampling

Phenazocine 1 mg.
(Sept. 1960—26 cases)
Phenazocine 2 mg.
(Oct. 1960—23 cases)
Phenazocine 2 mg.
(Oct. 1960—21 cases
Phenazocine 2 mg.
(Nov. 1960—25 cases)
Final Results
I mg.
2 mg.

GOOD

FAIR

POOR

30%

35%

35%

70%

26%

4% \

43%

34%

23% I

64%

28%

8%

44
63

31
25.5

(Against
Numorphan)
(Against
Each Oilier)
(Against
Morphine)

25
11.5

Table V I I I
Numorphan Pain Relief Sampling

Numorphan 1.5 mg.
(June 1960—25 cases)
Numorphan 1.5 mg.
(Nov. 1960—26 cases)
Final Results
1.5 mg.

GOOD

FAIR

POOR

64%

36%

0

73%

23%

4%

75

16

9
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(Against
Phenazocine 2 mg.)
(Against
Demerol 50 mg.

DITZLER.

DUMKE

AND

COLLIER

Beecher and others have reported that on the average 34 per cent of patients
receiving a placebo under such situations have pain relief. Does this mean, therefore,
that these final column percentages minus 34 per cent represent the true efficacy
of these various drugs, or should the placebo effect be discounted only in the
truly Good results rather than overall fair and good results? It makes a difference.
With Morphine, removing 34 per cent for placebo reactors from the definitely good
results (52 to 34 per cent), there remains only 18 per cent good; whereas 41
per cent of Numorphan good results might represent true drug response (75 to 34
per cent). It is probable that this placebo reactor may not be identifiable by pain
relief statistics alone but by the speed of onset of drug action.
Table V I I departs from the total results as just outlined and shows the variations
possible with the same drug when tested blindly against drugs of different efficacy,
against different doses and even with the given dose tested blindly against the same
dose in a concurrently run "blind" analgesic.
Three points are worthy of note:
(a)

2 mg. of Phenazocine is definitely better than 1 mg.

(b)

When comparing drugs of different potency the unknown test
tends to make the less potent appear less effective and the more
potent more effective.

It can be seen that 1 mg. of Phenazocine was poorer, when compared with
Numorphan, than its final average. Contrariwise, when 2 mg. of Phenazocine was
compared with Morphine Sulfate (which ultimately proved to be a less effective
drug), 2 mg. of Phenazocine appeared more effective than its final average.
(c)

The same drug and dose compared simultaneously as unknowns,
can provide wide variance if the same drug at a lower dosage
had been employed as a blind, immediately prior to the series
being tested. Note the comparison of the 2 mg. Phenazocine doses
simultaneously.

In like manner we contrasted Numorphan (Table V I I I ) . The same observation
applied; i.e., the more unequal the contrast, the greater the number of good results
appearing. One special observation is noted here which is reflected throughout the
Table I X
DURATION AND ONSET
Morphine Sulfate
Demerol
Demerol
Phenazocine
Phenazocine
Alvodine
Nurmorphan
Numorphan

III
50

100
1
2
20
1

1.5

mg.
mg.
mg.
mg.
mg.
mg.
mg.
mg.

MINUTES
90
50
75
60-90
60-120
90
90-150
120-180
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FAST
39%
30
48
32

MODERATE
40%
35
52
23

SLcnv
21%
35
0
45

36
60
37

35
15
33

25

29

67

ly

14
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series, which could be referred to as "predictability." On all counts, there was less
fluctuation in the variables with Numorphan. Numorphan "good" results more
nearly approached the final tabulation than did Phenazocine comparisons in Table V I I .
As mentioned earlier, it appears to us that Good results, regardless of the drug's
overall satisfaction, may be prejudicely assigned on the basis of rapidity of action
and consequent easing of the observer's task. As seen in Table IX, this may
account for the high percentage of good results with 1.5 mg. of Numorphan, but
it won't explain the small percentage of fast results with 1 mg. of Numorphan since
its "good" pain relief nearly equahed the 1.5 mg. dose. Nor does the poorer
showing of "good" pain relief with Alvodine (Table V I ) appear explainable with a
definitely fast onset, as shown (Table I X ) for Alvodine. Fast onset was defined
as up to 10 minutes, moderate onset as 10-20 minutes and slow onset as 20
minutes or longer. The duration figures are self-explanatory. Of passing note is
the supporting data that Demerol just isn't as long lasting as we would like.
It is of no value to our purpose if the price of pain relief is detrimental to
the patient's vital signs. This is summarized in Table X.
None of these drugs are innocuous. While 1 mg. doses of Phenazocine are less
often harmful, nonetheless it was still bad enough in one case, dropping blood
pressure 60 mm.; and further it was a poor pain reliever. In essence, the better the
pain relief, the more the respiratory and circulatory depression. There are two
additional comments necessary.
(1) Among the drugs which most effectively relieved pain Demerol 100 mg.
had the severest effect on respiration in our series.
(2) Among the drugs which were truly effective, all caused approximately the
same incidence of hypotension. In this series none of the hypotensive episodes with
Numorphan were adjudged to have been severe enough to require vasopressors —
which was not true of Demerol or Phenazocine.
In summarizing our resuhs we confess disappointment in not being able to
designate one drug as best for the PARR patient needing pain relief. From the
Table X

Morphine Sulfate
10 mg.
Demerol
50 mg.
Demerol
100 mg.
Phenazocine
1 mg.
Phenazocine
2 mg.
Alvodine
20 mg.
Numorphan
1 mg.
Numorphan
1.5 mg.
%=Percent of Patients having

DEPRESSION OF VITAL SIGNS
BLOOD PRESSURE
RESPIRATIONS
AVE.
MAX.
%
%
AVE
MAX.
3l%
30 mm.
40 mm.
39%
20
28%
15 mm.
50 mm.
33%
4
10
28%,
20 mm.
50 mm.
68%
4
8
15%
20 mm.
60 mm.
33%
3
4
22%
20 mm.
40 mm.
45%
4
6
20%
20 mm.
40 mm.
43%
6
li)
20%
15 mm.
30 mm.
46%
4
10
28%
20 mm.
35 mm.
43%
4
12
falls where BP 1 10 mm. Hg. or more and/or Resp.T, 2/min.
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tables presented it can be seen that while the numerical data is close in many
individual aspects, viewed as a composite (Table X I ) , certain drugs appear worthy
of consideration. We feel more extensive blind series should now be conducted
with Alvodine 20 mg., Numorphan 1 and 1.5 mg. and Phenazocine 2 mg.
SUMMARY

Meperidine in our judgment is not the best drug for the treatment of postoperative pain in the PARR patient. By our criteria there are better analgesics with
faster onset of action, duration and minimal side effects. Our low incidence of
5 per cent utilization of narcotics is in part due to the anesthetic and PARR
practices previously outlined. In our opinion, the speed of onset, the total number
of patients aided to any degree, as distinguished from only those receiving excellent
results, and the duration of action, may falsely influence the investigator assigning
a claim for a given drug.
Table X I
COMPOSITE OF RESULTS
Best Duration:
Fast Onset:
Least Deleterious Vital Sign Depression
(Of Truly Effective Pain Relieving Drugs):

Consistent Good Pain Relief:

(1
(2
(1
(2

Numorphan (120"-|-)
Phenazocine 2 mg. (90"~t-)
Numorphan 1.5 mg.
Alvodine 20 mg.

(I
(2
(3
(4
(I
(2
(3
(4
(5

Numorphan I mg.
Phenazocine 2 mg.
Alvodine 20 mg.
Numorphan 1.5 mg.
Numorphan 1.5 mg.
Demerol 100 mg.
Alvodine 20 mg.
Phenazocine 2 mg.
Numorphan 1 mg.

ADDENDUM

From February 1961 through February 1962 all patients in PARR with pain
were given numorphan. Clinical impressions were very favorable and appeared
superior in all ways to our prior clinical impressions with meperidine.
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